Pirfenidon

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Immunosuppressive agent for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF)

EffectsThis section has been translated automatically.

Pirfenidone is a small molecule active substance that can be taken orally. It inhibits the synthesis of several cytokines that are involved in inflammatory and fibrotic processes. For example, it inhibits the transforming growth factor TGF-beta. TGF-beta controls numerous cell functions, including proliferation and differentiation. The cytokine plays a key role in the development of fibrosis. Pirfenidone also inhibits the synthesis of TNF-alpha, a cytokine that is actively involved in inflammatory processes.

Trade namesThis section has been translated automatically.

Esbriet

Note(s)This section has been translated automatically.

Contraindication is severe liver or kidney dysfunction. Side effects affect the gastrointestinal tract (dyspepsia, nausea, diarrhea, GERD (Gastroesophageal reflux desease). Photosensitivity is also observed (direct UV exposure should be avoided).

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer